Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
67
CRL Quote, Financials, Valuation and Earnings
Last price:
$221.00
Seasonality move
:
4.63%
Day range:
$216.88 - $222.37
52-week range:
$91.86 - $222.37
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
2.76x
P/B ratio:
3.19x
Volume:
1.1M
Avg. volume:
674.7K
1-year change:
17.56%
Market cap:
$10.9B
Revenue:
$4B
EPS (TTM):
-$1.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$987.2M | $2.35 | -1.54% | 75.74% | $202.33 |
|
JNJ
Johnson & Johnson
|
$24.2B | $2.50 | 5.28% | -39.69% | $212.00 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $7.22 | 31.31% | 54.16% | $1,116.33 |
|
MRK
Merck & Co., Inc.
|
$16.2B | $2.04 | 5.87% | -31.4% | $111.62 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.7B | $10.53 | -0.81% | 32.75% | $824.69 |
|
UNH
UnitedHealth Group, Inc.
|
$113.7B | $2.11 | 12.47% | -64.72% | $393.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$220.91 | $202.33 | $10.9B | 913.13x | $0.00 | 0% | 2.76x |
|
JNJ
Johnson & Johnson
|
$204.39 | $212.00 | $492.4B | 19.73x | $1.30 | 2.52% | 5.38x |
|
LLY
Eli Lilly & Co.
|
$1,063.56 | $1,116.33 | $951.9B | 52.60x | $1.50 | 0.56% | 16.32x |
|
MRK
Merck & Co., Inc.
|
$110.53 | $111.62 | $274.3B | 14.62x | $0.85 | 2.97% | 4.36x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$796.55 | $824.69 | $83.7B | 19.07x | $0.88 | 0.44% | 6.16x |
|
UNH
UnitedHealth Group, Inc.
|
$343.98 | $393.85 | $311.6B | 17.95x | $2.21 | 2.54% | 0.72x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
43.59% | 1.827 | 33.97% | 0.85x |
|
JNJ
Johnson & Johnson
|
36.62% | -0.032 | 10.26% | 0.71x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.108 | 20.79% | 1.06x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | -0.094 | 4.57% | 3.19x |
|
UNH
UnitedHealth Group, Inc.
|
45.55% | -0.673 | 24.83% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$324.7M | $151.1M | -1.27% | -2.28% | 15.04% | $178.2M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
UNH
UnitedHealth Group, Inc.
|
-- | $4.3B | 9.95% | 17.57% | 2.85% | $5.1B |
Charles River Laboratories International, Inc. vs. Competitors
-
Which has Higher Returns CRL or JNJ?
Johnson & Johnson has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 21.47%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About CRL or JNJ?
Charles River Laboratories International, Inc. has a consensus price target of $202.33, signalling downside risk potential of -8.41%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could grow by 3.72%. Given that Johnson & Johnson has higher upside potential than Charles River Laboratories International, Inc., analysts believe Johnson & Johnson is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.10 7 0 JNJJohnson & Johnson9 11 0 -
Is CRL or JNJ More Risky?
Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.
-
Which is a Better Dividend Stock CRL or JNJ?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.52% to investors and pays a quarterly dividend of $1.30 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or JNJ?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Johnson & Johnson's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.76x versus 5.38x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.76x 913.13x $1B $55.6M JNJJohnson & Johnson5.38x 19.73x $24B $5.2B
-
Which has Higher Returns CRL or LLY?
Eli Lilly & Co. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 31.72%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About CRL or LLY?
Charles River Laboratories International, Inc. has a consensus price target of $202.33, signalling downside risk potential of -8.41%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,116.33 which suggests that it could grow by 4.96%. Given that Eli Lilly & Co. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Eli Lilly & Co. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.10 7 0 LLYEli Lilly & Co.18 7 0 -
Is CRL or LLY More Risky?
Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock CRL or LLY?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or LLY?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Eli Lilly & Co.'s PE ratio is 52.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.76x versus 16.32x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.76x 913.13x $1B $55.6M LLYEli Lilly & Co.16.32x 52.60x $17.6B $5.6B
-
Which has Higher Returns CRL or MRK?
Merck & Co., Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 33.68%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About CRL or MRK?
Charles River Laboratories International, Inc. has a consensus price target of $202.33, signalling downside risk potential of -8.41%. On the other hand Merck & Co., Inc. has an analysts' consensus of $111.62 which suggests that it could grow by 0.98%. Given that Merck & Co., Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Merck & Co., Inc. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.10 7 0 MRKMerck & Co., Inc.15 12 0 -
Is CRL or MRK More Risky?
Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.
-
Which is a Better Dividend Stock CRL or MRK?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.85 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or MRK?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Merck & Co., Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.76x versus 4.36x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.76x 913.13x $1B $55.6M MRKMerck & Co., Inc.4.36x 14.62x $17.2B $5.8B
-
Which has Higher Returns CRL or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 38.89%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About CRL or REGN?
Charles River Laboratories International, Inc. has a consensus price target of $202.33, signalling downside risk potential of -8.41%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $824.69 which suggests that it could grow by 3.53%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.10 7 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is CRL or REGN More Risky?
Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock CRL or REGN?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or REGN?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.76x versus 6.16x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.76x 913.13x $1B $55.6M REGNRegeneron Pharmaceuticals, Inc.6.16x 19.07x $3.8B $1.5B
-
Which has Higher Returns CRL or UNH?
UnitedHealth Group, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 2.25%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B UNHUnitedHealth Group, Inc.-- $2.59 $185.9B -
What do Analysts Say About CRL or UNH?
Charles River Laboratories International, Inc. has a consensus price target of $202.33, signalling downside risk potential of -8.41%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $393.85 which suggests that it could grow by 14.5%. Given that UnitedHealth Group, Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe UnitedHealth Group, Inc. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.10 7 0 UNHUnitedHealth Group, Inc.14 6 2 -
Is CRL or UNH More Risky?
Charles River Laboratories International, Inc. has a beta of 1.613, which suggesting that the stock is 61.299% more volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.420, suggesting its less volatile than the S&P 500 by 57.978%.
-
Which is a Better Dividend Stock CRL or UNH?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $2.21 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. UnitedHealth Group, Inc. pays out 52.75% of its earnings as a dividend. UnitedHealth Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or UNH?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than UnitedHealth Group, Inc.'s net income of $2.5B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while UnitedHealth Group, Inc.'s PE ratio is 17.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.76x versus 0.72x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.76x 913.13x $1B $55.6M UNHUnitedHealth Group, Inc.0.72x 17.95x $113.2B $2.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
